Evidence map›Paper›PMID 29444690›Full record

Trial reportEnvironmental health : a global access science source2018

Efficacy of N,N'bis-(2-mercaptoethyl) isophthalamide on mercury intoxication: a randomized controlled trial.

Paul Schutzmeier, Augusto Focil Baquerizo, Wilson Castillo-Tandazo, Nicholas Focil, Stephan Bose-O'Reilly

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Environmental health : a global access science source, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02486289 (A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02486289 phase2completednot on this map

A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population

TypeinterventionalSponsorEmeraMedRan2015 to 2016Enrolled36ConditionsMercury PoisoningArmsEmeramide, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paul SchutzmeierInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, WHO Collaborating Centre for Occupational Health, University Hospital Munich, Ziemssenstr. 1, D-80336, Munich, Germany. paul.schutzmeier@med.uni-muenchen.de.ORCID 0000-0002-3248-560X
Augusto Focil BaquerizoFOMAT Medical Research, Oxnard, CA, USA.
Wilson Castillo-TandazoFOMAT Medical Research, Oxnard, CA, USA.
Nicholas FocilFOMAT Medical Research, Oxnard, CA, USA.
Stephan Bose-O'ReillyInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, WHO Collaborating Centre for Occupational Health, University Hospital Munich, Ziemssenstr. 1, D-80336, Munich, Germany.

Funding

EmeraMed NoneHEALS project by DG Research Grant agreement No.: 603946
6 · The paper itself

Abstract

backgroundChronic mercury intoxication is a severe health issue and occurs especially in gold mining communities. Common chelators used for improving mercury elimination are not everywhere available and challenged by poor cell wall penetration. This study is part of a feasibility trial and the aim was to gather first information about the efficacy of the newly developed chelator N,N'bis-(2-mercaptoethyl) isophthalamide (NBMI) on chronic mercury intoxication.

methodsIn this three-armed, placebo-controlled randomized trial, 36 miners with mercury urine levels exceeding 15 μg/l were administered 100 mg NBMI, 300 mg NBMI or placebo for 14 days. Levels of mercury in urine [μg/l and μg/g creatinine] and plasma l were analyzed. Therapeutic effect was assessed using the medical intoxication score (MIS) and its single health outcomes (e.g. excessive salivation, sleeping problems), fatigue scores, a neuromotoric test battery (CATSYS) and a neurological outcome (Finger to nose test).

resultsPhysical fatigue was significantly decreased in the 300 mg NBMI group compared to the control. Mercury concentration in urine following 300 mg NBMI treatment was significantly lowered compared to control, however, this effect was less distinct with adjustment for creatinine.

conclusionNBMI showed an effect on physical fatigue and there were indications to positive effects on other symptoms as well. More comprehensive studies are mandatory to verify the effects of NBMI as a novel tool for treating mercury intoxications.

trial registrationClinicalTrials.gov Identifier: NCT02486289 . Date of registration: June 24, 2015.

Indexed as

Occupational ExposureAdultChelating AgentsCysteamineDose-Response Relationship, DrugEnvironmental PollutantsGoldHispanic or LatinoHumansMaleMercuryMercury PoisoningMiddle AgedMiningPhthalic AcidsYoung AdultChelating AgentsCysteamineEnvironmental PollutantsGoldMercuryN,N'-bis-2-mercaptoethylisophthalamidePhthalic AcidsChelation therapyChronic mercury intoxicationGold miningMercuryNBMI

Identifiers

PMID29444690
PMCPMC5813329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.